The American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting brought together leaders across the ophthalmology community this spring, offering a platform to explore the latest clinical innovations, connect with partners and strengthen the field.
Eversight was proud to attend to support educational wet labs, learn from global experts and explore emerging strategies that align closely with our mission to restore sight and prevent blindness.
ASCRS 2025 delivered high-quality sessions, well-executed programming and meaningful interactions.
“The event was beautifully organized with a strong vendor presence and a diverse range of presentations,” said Eversight Global Development Director Carrie Wolverton. “The conference itself was very well done and offered a positive overall experience.”
Exploring new frontiers in corneal disease treatment
Several sessions focused on cutting-edge molecular approaches to corneal disease—including gene and cell therapies designed to address root causes rather than symptoms.
Both Carrie and Eversight Vice President of Business Development Caithlin Lopes, highlighted the future of new treatments like DSO (Descemet stripping only), injected cultured cells and allogenic cell therapy.
“All very exciting and I am thrilled Eversight is a part of it through our work with Emmecell,” Caithlin said.
Carrie was surprised to learn about the patient recovery timeline for injectable human endothelial cells. These treatments, while promising, may require significantly longer recovery compared to traditional DMEK, which has important implications for patient care and expectations.
KLAL-Pro: Reinforcing a commitment to innovation
A standout moment for Caithlin came during Cornea Day, when Edward J. Holland, MD, spoke on the treatment for patients with complete limbal stem cell loss and the evolution of keratolimbal allografts (KLA). Caithlin connected with Dr. Holland directly following his lecture and discussed his findings in light of Eversight’s recent KLAL-Pro launch.
“That conversation got me even more excited about the impact KLAL-Pro will have on those patients with complete limbal stem cell loss,” she said.
Building community in hands-on wet labs
The Eversight team once again supported several wet labs, including a DALK session that has seen increasing attendance since its inception three years ago.
What began as a small initiative now sells out at full capacity, offering invaluable hands-on experience to early-career ophthalmologists.
“There was so much positive energy,” Carrie said. “The smiles, engaged conversations and enthusiasm made it clear how meaningful this hands-on learning was for the participating doctors.”
A space for collaboration and connection
ASCRS remains an important opportunity for in-person collaboration with eye bank partners, surgeons and industry colleagues. Caithlin emphasized how valuable these face-to-face conversations are for deepening relationships and sparking new ideas.
Carrie expressed optimism about upcoming global meetings like the European Society of Cataract and Refractive Surgeons (ESCRS). And of course, there were some lighter moments too.
“I got to meet Dr. Glaucomflecken!” Caithlin added with a smile.
Looking ahead
As the field of ophthalmology continues to explore new treatments and technologies, Eversight is proud to stand alongside leading innovators—providing high-quality ocular tissue and advancing therapies that restore vision and transform lives.
From wet labs to keynote lectures, ASCRS 2025 affirmed the importance of staying connected, curious and collaborative in pursuit of Eversight's mission.
“We’re right there at the forefront, working alongside some of the best in the field,” Carrie said. “That makes me genuinely proud.”
Share this Post
Interested in receiving periodic news and updates from Eversight? We invite you to sign up to receive our emails.
